Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...
Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that ...
Guardant Health ( NASDAQ: GH) traded higher in the morning hours on Tuesday after the company announced that the U.S. Centers ...
Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid ...
Guardant Health (NASDAQ:GH – Free Report) had its target price lifted by Morgan Stanley from $42.00 to $52.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating ...
The Daily Record on MSN6d
Vaccines: A shield against disease – local experts weigh in on the benefitsIt's smart for parents to ask questions, but "the overwhelving evidence tells us vaccines are safe, effective and critical," ...
Principal Financial Group Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 8.0% in ...
There is a new and less invasive option to test for colon cancer and it doesn’t require a stay at the hospital or mailing a stool sample.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback